Combining Inhalation by A Breath Actuated Nebuliser (BAN) With Exhalation Through An Oscillating Positive Expiratory Pressure Device (OPEP) Offers The Potential For Optimal Combined Therapy

Conclusions: The delivery of medication from the AEROECLIPSE* II BAN to the lungs was not significantly affected by the incorporation of the Aerobika* OPEP device. This therapy could offer the clinician the opportunity for combined aerosol/OPEP therapy (ie in cystic fibrosis patients) thereby reducing the time needed for the patient to take nebuliser and OPEP treatment separately.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Nagel, M., Suggett, J., Kushnarev, V., Coppolo, D., Wesolowski, A., Corcoran, T. Tags: Cystic fibrosis Source Type: research